Sign in
CompletedPhase 3

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Key facts

Who runs it
Seqirus
Where
Albuquerque, Asheville, Atlanta, Aurora, Baton Rouge, Beachwood, Binghamton, Birmingham, Boynton Beach, Brookline, Charleston, Charlottesville, Chattanooga, Chicago, Cincinnati, Clarkston, Clearwater, Columbus, Covington, Crystal River, Cullman, Dallas, Doral, Dublin, Durham, East Greenwich, East Syracuse, Edgewater, Encino, Farmington Hills, Fleming Island, Fort Worth, Gaffney, Gainesville, Grand Island, Gulfport, Houston, Inglewood, Jacksonville, Jersey City, Jupiter, Kansas City, Kingwood, Knoxville, La Mesa, Lafayette, Lake Worth, Largo, Las Vegas, Little Rock, Long Beach, Longmont, Medford, Melrose Park, Meridian, Metairie, Methuen, Miami, Miami Lakes, Milford, Missoula, Modesto, Monroe, Nashville, Norfolk, North Charleston, North Las Vegas, Omaha, Pembroke Pines, Phoenix, Pittsburgh, Plano, Raleigh, Redding, Richmond, Saint Augustine, San Antonio, San Diego, Sandy Springs, Savannah, Scottsdale, Seattle, Sioux City, Southfield, Spartanburg, St Louis, Suffolk, Sugar Land, Sunrise, Tampa, Tomball, Union, Valparaiso, Waterbury, Wheat Ridge, Wilmington, Winston-Salem, Woodstock, and Yukon, United StatesSee the 111 sitesAlso in 20 other countries, 146 sites
Status
Completed
Phase
Phase 3
People taking part
38,769 people enrolled
Started
23 Oct 2023
Ended
15 Jun 2026
Type of study
Interventional, 2 groups
Treatments tested
  • aQIV or aTIV
  • QIV or TIV
Record updated
2 September 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • In order to participate in this study, all subjects must meet ALL of the inclusion criteria described
  • Adults of ≥65 years of age on the day of vaccination
  • Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
  • Individuals who have the ability to comply with study procedures including follow-up

Who cannot take part

  • Receipt of any influenza vaccine within 6 months prior to enrollment or any plan to receive influenza vaccine while participating in the study
  • Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study, or severe allergic reaction (e.g. anaphylaxis) to previous influenza vaccination
  • Abnormal function of the immune system resulting from:; Clinical conditions; Systemic administration of corticosteroids (PO/IV/IM) at a dose ≥20 mg/day of prednisone (or equivalent) for more than 14 consecutive days within 90 days prior to informed consent; Topical, inhaled and intranasal corticosteroids are permitted. Intermittent use (one dose in 30 days) of intra-articular corticosteroids are also permitted; Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent
  • Receipt of immunoglobulins or any blood products within 180 days prior to informed consent
  • Receipt of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the study vaccination, or planned use during the entire study period
  • Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis
  • Clinical conditions representing a contra-indication to intramuscular administration of vaccines or blood draw
  • Acute (severe) febrile illness
  • Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study
  • Bedridden subjects (i.e. confined to bed by sickness or old age)
  • In order to participate in this study, all subjects must not meet any of the exclusion criteria described below:
  • Subjects that are incapacitated and because of that in need of a Legally Authorized Representative
  • Study personnel or immediate family members (brother, sister, child, parent) or the spouse of study personnel

Where in United States

Also in 20 other countries, 146 sites

  • 84122-Albuquerque Clinical TrialsAlbuquerque, United States
  • 84014-Asheville Clinical ResearchAsheville, United States
  • 84037-Eximia Research - GAAtlanta, United States
  • 84086-Agile Clinical Research Trials, LLCAtlanta, United States
  • 84125-Lynn Institute of DenverAurora, United States
  • 84055-Velocity Clinical Research - Baton RougeBaton Rouge, United States
  • 84021-Velocity Clinical Research - ClevelandBeachwood, United States
  • 84048-Velocity Clinical Research - BinghamtonBinghamton, United States
  • 84046-Accel Research Sites - BirminghamBirmingham, United States
  • 84029-Imagine Research of Palm Beach CountyBoynton Beach, United States
  • 84005-DM Clinical Research - BrooklineBrookline, United States
  • 84010-M3 Wake Research/Charleston Clinical Trials, LLCCharleston, United States
  • 84049-Charlottesville Medical ResearchCharlottesville, United States
  • 84068-WR-ClinSearch, LLCChattanooga, United States
  • 84060-Great Lakes Clinical Trials LLC, dba Flourish ResearchChicago, United States
  • 84034-CTI Clinical Research CenterCincinnati, United States
  • 84063-Velocity Clinical Research - Cincinnati (Mt. Auburn)Cincinnati, United States
  • 84044-Clarkston Medical GroupClarkston, United States
  • 84067-Innovative Research of West Florida, Inc.Clearwater, United States
  • 84054-Centricity Research ColumbusColumbus, United States
  • 84088-Velocity Clinical Research - CovingtonCovington, United States
  • 84006-Nature Coast Clinical Research - Crystal RiverCrystal River, United States
  • 84075-Cullman Clinical TrialsCullman, United States
  • 84072-WR-Global Medical Research, LLCDallas, United States
  • 84016-USA and International Research Inc.Doral, United States
  • 84101-West Coast Research LLCDublin, United States
  • 84089-Velocity Clinical Research - DurhamDurham, United States
  • 84009-Velocity Clinical Research - ProvidenceEast Greenwich, United States
  • 84077-Velocity Clinical Research - SyracuseEast Syracuse, United States
  • 84061-Velocity Clinical Research - New Smyrna BeachEdgewater, United States
  • 84124-Leading Edge ResearchEncino, United States
  • 84018-Quest Research InstituteFarmington Hills, United States
  • 84032-Bioscope Clinical Research, LLCFarmington Hills, United States
  • 84065-Fleming Island Center for Clinical ResearchFleming Island, United States
  • 84028-Benchmark ResearchFort Worth, United States
  • 84043-Velocity Clinical Research - GaffneyGaffney, United States
  • 84027-SIMEDHealth, LLCGainesville, United States
  • 84030-Velocity Clinical Research - Grand IslandGrand Island, United States
  • 84023-Velocity Clinical Research - GulfportGulfport, United States
  • 84015-Trio Clinical Trials LLCHouston, United States
  • 84104-Zillan Clinical ResearchInglewood, United States
  • 84019-Green Leaf Clinical TrialsJacksonville, United States
  • 84003-DM Clinical Research - New JerseyJersey City, United States
  • 84026-Health Awareness, Inc.Jupiter, United States
  • 84038-Kansas City Research InstituteKansas City, United States
  • 84062-Activian Clinical ResearchKingwood, United States
  • 84090-Alliance for Multispecialty Research, LLCKnoxville, United States
  • 84105-Eximia Research - CALa Mesa, United States
  • 84052-Velocity Clinical Research - LafayetteLafayette, United States
  • 84071-3SYNC ResearchLake Worth, United States
  • 84083-Accel Research Sites Network - St. Petersburg-LargoLargo, United States
  • 84103-Alliance for Multispecialty Research, LLCLas Vegas, United States
  • 84111-Vector Clinical TrialsLas Vegas, United States
  • 84117-M3 Wake Research/CRCNLas Vegas, United States
  • 84045-Lynn Institute of the OzarksLittle Rock, United States
  • 84070-Baptist Health Center for Clinical ResearchLittle Rock, United States
  • 84107-Long Beach Research InstituteLong Beach, United States
  • 84109-Long Beach Clinical TrialsLong Beach, United States
  • 84110-Tekton ResearchLongmont, United States
  • 84121-Velocity Clinical Research - MedfordMedford, United States
  • 84022-DM Clinical Research - River ForestMelrose Park, United States
  • 84118-Velocity Clinical Research - BoiseMeridian, United States
  • 84064-Benchmark ResearchMetairie, United States
  • 84002-ActivMed Practices and Research, LLCMethuen, United States
  • 84012-Evolution Clinical TrialsMiami, United States
  • 84082-Global Health Research Center, Inc.Miami Lakes, United States
  • 84085-Clinical Research Consulting, LLCMilford, United States
  • 84108-Boeson Research MSOMissoula, United States
  • 84115-Central Valley ResearchModesto, United States
  • 84035-Monroe Biomedical ResearchMonroe, United States
  • 84084-Clinical Research Associates, Inc.Nashville, United States
  • 84040-Velocity Clinical Research - NorfolkNorfolk, United States
  • 84056-Coastal Carolina Research Center, LLCNorth Charleston, United States
  • 84106-Las Vegas Clinical TrialsNorth Las Vegas, United States
  • 84007-Velocity Clinical Research - OmahaOmaha, United States
  • 84081-Suncoast Research Associates, LLCPembroke Pines, United States
  • 84112-DM Clinical Research - PhoenixPhoenix, United States
  • 84050-3SYNC ResearchPittsburgh, United States
  • 84031-North Texas Family MedicinePlano, United States
  • 84066-Research Your HealthPlano, United States
  • 84080-ACRC TrialsPlano, United States
  • 84020-M3 Wake Research/Raleigh Clinical Research, LLCRaleigh, United States
  • 84102-Eximia Research - NCRaleigh, United States
  • 84120-Paradigm ResearchRedding, United States
  • 84058-Clinical Research PartnersRichmond, United States
  • 84024-St. Johns Center for Clinical ResearchSaint Augustine, United States
  • 84011-Clinical Trials of Texas, LLC, dba Flourish ResearchSan Antonio, United States
  • 84076-DM Clinical Research - San AntonioSan Antonio, United States
  • 84119-Apex Clinical ResearchSan Diego, United States
  • 84013-M3 Wake Research/Mount Vernon Clinical Research, LLCSandy Springs, United States
  • 84069-Velocity Clinical Research - SavannahSavannah, United States
  • 84114-Scottsdale Clinical TrialsScottsdale, United States
  • 84113-DM Clinical Research - SeattleSeattle, United States
  • 84042-Velocity Clinical Research - Sioux CitySioux City, United States
  • 84001-Revival Research Institute, LLCSouthfield, United States
  • 84074-DM Clinical Research - SouthfieldSouthfield, United States
  • 84047-Velocity Clinical Research - SpartanburgSpartanburg, United States
  • 84057-Sundance Clinical ResearchSt Louis, United States
  • 84036-Velocity Clinical Research - SuffolkSuffolk, United States
  • 84059-DM Clinical Research - Sugar LandSugar Land, United States
  • 84051-Precision Clinical ResearchSunrise, United States
  • 84008-Global Health Research Center, Inc. - TampaTampa, United States
  • 84087-DM Clinical Research - TomballTomball, United States
  • 84053-Velocity Clinical Research - UnionUnion, United States
  • 84025-Velocity Clinical Research - ValparaisoValparaiso, United States
  • 84017-Chase Medical Research, LLCWaterbury, United States
  • 84123-Paradigm ResearchWheat Ridge, United States
  • 84004-TMA Headlands LLC, dba Trial Management AssociatesWilmington, United States
  • 84079-Progressive Medicine of the Triad, LLCWinston-Salem, United States
  • 84039-North Georgia Clinical ResearchWoodstock, United States
  • 84078-Tekton ResearchYukon, United States

About the trial

What the trial wants to find out

This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.

The 2 groups in the trial

  • MF59-adjuvanted influenza vaccineTreatment being tested

    MF59-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains or MF59-adjuvanted TIV containing 2 influenza type A strains and 1 influenza type B strain

    Treatment: aQIV or aTIV

  • Non-adjuvanted influenza vaccineOther group

    Non-adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains or Non-adjuvanted TIV containing 2 influenza type A strains and 1 influenza type B strain

    Treatment: QIV or TIV

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad Quadrivalent Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Record updated
2 September 2026